Cooling for newborns with hypoxic ischaemic encephalopathy

Area of Science:

• Neonatal medicine
• Perinatal neurology
• Clinical trials

Background:

• Newborn animal and pilot human studies suggest mild hypothermia post-hypoxia-ischaemia may reduce neurological sequelae without adverse effects.
• Hypoxic-ischaemic encephalopathy (HIE) is a serious condition in newborns resulting from oxygen deprivation during birth.

Purpose of the Study:

• To evaluate the impact of therapeutic hypothermia on mortality, long-term neurodevelopmental disability, and side effects in newborns with HIE.
• To synthesize evidence from randomized controlled trials on the efficacy and safety of cooling therapy for HIE.

Main Methods:

• Systematic review and meta-analysis of eight randomized controlled trials involving 638 term infants with HIE.
• Searched multiple databases including Cochrane Library, CENTRAL, and MEDLINE for relevant trials.
• Primary outcome: death or major neurodevelopmental disability at 18 months; secondary outcomes: adverse effects and early neurodevelopmental indicators.

Main Results:

• Therapeutic hypothermia significantly reduced the combined outcome of mortality or major neurodevelopmental disability (NNT=7).
• Cooling therapy led to statistically significant reductions in mortality (NNT=11) and neurodevelopmental disability in survivors (NNT=8).
• Observed adverse effects included a borderline increase in inotrope support and a significant increase in thrombocytopenia.

Conclusions:

• Therapeutic hypothermia is beneficial for term newborns with HIE, reducing mortality without increasing disability in survivors.
• The benefits of cooling on survival and neurodevelopment outweigh short-term adverse effects.
• Further trials are needed to confirm findings with larger sample sizes and explore optimal cooling methods.